converting between glp-1 agonists The Cardiovascular Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-Level Outcomes to Micro-Level Mechanisms Switching Between Glucagon-Like Peptide-1 Receptor

Data represents mean SEM

Semaglutide was dosed for the full period, while antibody dosing with the -MSTN and -ActA antibodies was started in Week 2 as an add-on to semaglutide and dosed through Week 12 (and was presumed to have more durable actions due to the extended half-life of the antibodies)

Patients in whom heart failure (HF) or chronic kidney disease (CKD) is prevalent, should receive a treatment intensification with an SGLT-2 inhibitor with the respective evidence from clinical studies due to the respective data (7072)

2026 EllieMD LLC

Kamran Zamanian, Ph.D., is CEO and founding partner of iData Research

7.3 Emerging predictive tools Novel innovations in radiology and machine learning have made it possible to quantitatively measure pancreatic fibrosis and -cell reserve